TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05376735

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Purrble intervention
Description: The intervention takes the form of an interactive plush toy, designed to be handed over to the child and support in-the-moment soothing.~The Purrble is introduced to the student as an anxious creature that may need kind attention from humans. When picked up, the Purrble emits a frantic heartbeat that slows down if the child uses calm stroking movements. If it's soothed for long enough, it transitions into a purring vibration indicating a calm, content state.~Logic model underlying the intervention:~Level 1: in-the-moment soothing support to students in emotional moments when they would attempt to practice emotion regulation (ER) strategies to calm down.~Level 2: mechanisms that facilitate long-term engagement with the intervention, building on positive subjective experience of Level 1.~Level 3: shift in students' ER practices and implicit beliefs about emotion, after repeated experience of Levels 1-2.
Study: NCT06457503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: In the event of cisplatin-related nephrotoxicity or at the discretion of the investigator due to cisplatin-related poor tolerability, carboplatin can substitute for cisplatin use from cycle 2 onward. These participants will receive carboplatin via IV on Day 1 Q3W during the Chemotherapy-based treatment phase.
Study: NCT05446090

Intervention type: DIAGNOSTIC_TEST
Intervention: Throat swab
Description: A throat swab will be taken at the baseline (attack) visit for viral identification.
Study: NCT05376735

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single Session Intervention
Description: The SSI has been co-produced with university students and clinical experts, combining the theories of ER with the qualitative experiences of students in open trial.~The result follows a traditional SSI structure (cf., Schleider et al 2020), including~* Initial guided reflection exercise (helping understand one's experience with Purrble in the 1st week).~* Short interactive psychoeducation, introducing the concept of window of tolerance, the Process Model of Emotions (Gross2015), and specific ways in which Purrble can help students down-regulate emotions within the context of the process model.~* Action plan to identify: moments when Purrble could be useful, what ER strategies they would like to use in those moments, what obstacles they may encounter, and how to overcome them.~The SSI will be accessible by students on a website and be both desktop and mobile browser friendly. The full process should not take students longer than 30 minutes.
Study: NCT05446090

Intervention type: DIAGNOSTIC_TEST
Intervention: Nasal Brush.
Description: Nasal brushings samples may be taken at baseline (attack) and at second visits for RNA and DNA extraction. This will be optional and specific consent from participants will be sought. Procedures for sampling and processing will be detailed in a study SOP.

Intervention type: DIAGNOSTIC_TEST
Intervention: Nasal absorption
Description: Nasal absorption will be used to collect mucosal lining fluid from the respiratory tract for cytokines profiling at baseline (attack) and at second visits.

Intervention type: OTHER
Intervention: Medical History, Demographic, and Concomitant Medications
Description: Medical history will include clinically significant diseases and prior surgeries and smoking history. A specific respiratory history will also be recorded. Demographic data will include age, sex and self- reported race/ethnicity. Medication use will also be collected.

Intervention type: OTHER
Intervention: Sino-nasal Outcome Test
Description: The incidence of upper airway symptoms will be assessed using Sino-nasal Outcome Test (SNOT).

Intervention type: OTHER
Intervention: Gastroesophageal Reflux Disease Questionnaire
Description: The incidence of Gastroesophageal Reflux Disease will be assessed using GERDQ questionnaire.

Intervention type: OTHER
Intervention: Pittsburgh Vocal Cord Dysfunction Index
Description: The incidence of vocal cord dysfunction will be assessed using Pittsburgh Vocal Cord Dysfunction (VCD) Index

Intervention type: OTHER
Intervention: Nijmegen Questionnaire.
Description: The incidence of dysfunctional breathing will be assessed using Nijmegen dysfunctional questionnaire.

Intervention type: OTHER
Intervention: Hospital Anxiety and Depression Scale
Description: The incidence of anxiety and depression will be assessed using Hospital Anxiety and Depression Scale (HADS).

Intervention type: OTHER
Intervention: Compliance and adherence
Description: In order to assess adherence as a factor in exacerbations, a participant's beliefs and attitudes towards medicines will be explored using the Medicines Adherence Report Scale (MARS) questionnaire. Non-intentional non-compliance with usual treatment will be assessed by checking inhaler technique; poor inhaler technique will be reported to the participant's clinical team. Also, GP records will be reviewed for information on medications prescribed in the last 12 months.

Intervention type: OTHER
Intervention: Acute Asthma Quality of Life Questionnaire
Description: The impact of acute asthma on quality of life will be assessed using Acute Asthma Quality of Life Questionnaire at baseline and follow up.
Study: NCT06081725

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Playful interactions in an online format
Description: The activity is grounded in dramatic improvisation and comprises several games: a ball game, an association game, a mirror game, a movement story game. The intervention will be conducted by zoom

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Playful interactions in an online format
Description: The activity is grounded in dramatic improvisation and comprises several games: a ball game, an association game, a mirror game, a movement story game. The intervention will be conducted by zoom

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: An active control condition in a face-to-face format
Description: The activity consisted of three parts: A structured conversation centered around hobbies. In the second part an exercise in words - singular plural. In the third part, participants will be engaged in a movement practice resembling an exercise class.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: An active control condition in a face-to-face format
Description: The activity consisted of three parts: A structured conversation centered around hobbies. In the second part an exercise in words - singular plural. In the third part, participants will be engaged in a movement practice resembling an exercise class.
Study: NCT05178615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: preoperative education
Description: Education about knee anatomy, patophysiology, total knee arthroplasty surgery, pain neurophysiology, management of pain, the importance of exercise
Study: NCT04771572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-118
Description: novel, oral, selective treatment for hematological malignancies tested through ascending dose levels

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-118
Description: novel, oral, selective treatment for hematological malignancies tested through ascending dose levels
Study: NCT05428774

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test product 1
Description: Participants will receive TP1 during one experimental visit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test product 2
Description: Participants will receive TP2 during one experimental visit.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo during one experimental visit.
Study: NCT04781803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Cyclosporine 6 mg/kg and mycophenolic acid 1 gram orally on day 0 post-transplant
Study: NCT06125652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti Tim-3/CD123 CAR-T cell therapy
Description: Enrolled patients will receive prespecified dose of autologous CAR-T cells.
Study: NCT04397679

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D CRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy (IMRT)
Description: Undergo IMRT
Study: NCT06081725

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: An active control condition in an online format
Description: The activity consisted of three parts: A structured conversation centered around hobbies. In the second part an exercise in words - singular plural. In the third part, participants will be engaged in a movement practice resembling an exercise class. The intervention will be conducted conducted by zoom

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: An active control condition in an online format
Description: The activity consisted of three parts: A structured conversation centered around hobbies. In the second part an exercise in words - singular plural. In the third part, participants will be engaged in a movement practice resembling an exercise class. The intervention will be conducted conducted by zoom
Study: NCT04397679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields Therapy (TTF)
Description: Undergo TTF
Study: NCT05382702

Intervention type: OTHER
Group type: OTHER
Intervention: Test meal description changed
Description: Using a within-subjects crossover design, on two separate mornings participants will eat yogurt described as 'high fat' and 'low fat.' In actuality, the meals will not differ.

Intervention type: OTHER
Group type: OTHER
Intervention: Test meal description changed
Description: Using a within-subjects crossover design, on two separate mornings participants will eat yogurt described as 'high fat' and 'low fat.' In actuality, the meals will not differ.
Study: NCT05785624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vixarelimab
Description: Vixarelimab will be administered as per the schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vixarelimab
Description: Vixarelimab will be administered as per the schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vixarelimab
Description: Vixarelimab will be administered as per the schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vixarelimab
Description: Vixarelimab will be administered as per the schedule specified in the respective arms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as per the schedule specified in the respective arms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as per the schedule specified in the respective arms.
Study: NCT04899349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Alpelisib (tablets) administered at 300mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 8 in a 28 days cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpelisib
Description: Alpelisib (tablets) administered at 300mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 8 in a 28 days cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant (prefilled syringe) 500mg administered intramuscularly at Cycle 1 Day 1 and 15 after randomization and then at Day 1 of each subsequent cycle during the randomized treatment phase.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant (prefilled syringe) 500mg administered intramuscularly at Cycle 1 Day 1 and 15 after randomization and then at Day 1 of each subsequent cycle during the randomized treatment phase.
Study: NCT06081725

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Playful interactions in a face to face format
Description: The activity is grounded in dramatic improvisation and comprises several games: a ball game, an association game, a mirror game, a movement story game.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Playful interactions in a face to face format
Description: The activity is grounded in dramatic improvisation and comprises several games: a ball game, an association game, a mirror game, a movement story game.
Study: NCT05953922

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: core stability exersises
Description: core stability exercises and transcutaneous electrical nerve stimulation for four week three session per week
Study: NCT04839588

Intervention type: OTHER
Intervention: Usability study
Description: Participants will first be screened for propensity to simulation sickness and for cognitive state using the MoCA evaluation test. Those who passed the screening will perform 4 usability sessions rating the ease of use and perceived benefit of the experimental system and of a caregiver interface laptop. The 2 healthy volunteers will evaluate first, such that issues may be resolved before testing is done on the impaired participants. Each session will be compensated with a $35 payment. During each session participants will play a series of increasing difficulty simulated tasks, aimed to train primarily the executive functions domain. At the end of each session participants will rate their experience using custom subjective evaluation forms with multiple items. Each item will be scored using a 5-point Likert scale. At the end of the 4th session, participants will also fill the USE standardized usability form.~This usability evaluation will be conducted at the NJ Bioscience Center.
Study: NCT06129552

Intervention type: PROCEDURE
Intervention: Conchotomy, aesthetic nose surgery or functional endoscopic sinus operation
Description: Conchotomy involves the reduction or removal of hypertrophic nasal turbinates, aesthetic nose surgery is a surgical procedure that aims to enhance the appearance of the nose, while functional endoscopic sinus surgery is a minimally invasive procedure focused on treating sinus conditions by removing obstructions and improving sinus drainage.

Intervention type: PROCEDURE
Intervention: Conchotomy, aesthetic nose surgery or functional endoscopic sinus operation
Description: Conchotomy involves the reduction or removal of hypertrophic nasal turbinates, aesthetic nose surgery is a surgical procedure that aims to enhance the appearance of the nose, while functional endoscopic sinus surgery is a minimally invasive procedure focused on treating sinus conditions by removing obstructions and improving sinus drainage.

Intervention type: PROCEDURE
Intervention: Conchotomy, aesthetic nose surgery or functional endoscopic sinus operation
Description: Conchotomy involves the reduction or removal of hypertrophic nasal turbinates, aesthetic nose surgery is a surgical procedure that aims to enhance the appearance of the nose, while functional endoscopic sinus surgery is a minimally invasive procedure focused on treating sinus conditions by removing obstructions and improving sinus drainage.
Study: NCT03720483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine then Placebo
Description: Subject will receive N-acetyl cysteine first followed by Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo then N-acetyl cysteine
Description: Subject will receive Placebo first followed by N-acetyl cysteine
Study: NCT04878406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0480-0389
Description: A single dose of subcutaneous NNC0480-0389. The study will last for a maximum of 72 days.
Study: NCT05374408

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: BBN for Trauma Informed Care
Description: Brief explanation of BBN will be provided. Patient will be directed to areas of the app that are congruent with treatment focus identified during their standard of care appointment.~Patient will complete by going online or being contacted by a member of the research team member. The research assistant will contact all the patients in 2-3 days to help the patient navigate the BBN and complete the baseline survey if needed.~The patient will continue to meet with their BHP as determined by the standard of care interactions. BHP will highlight features contained in BBN for patient to use in between appointments.~Follow-up phone calls will be scheduled for 2 week and 6 weeks after the initial visit. During these phone- calls the participant will be contacted by a member of the research team to complete follow-up surveys.
Study: NCT04695249

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure intervention using 360 degree videos
Description: The intervention consists of eleven sessions. The first five sessions are dedicated to functional assessment and psychoeducation. The second five sessions are dedicated to exposure in 360-degree videos. The last session is provided for relapse prevention.
Study: NCT04878406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0480-0389
Description: A single dose of subcutaneous NNC0480-0389. The study will last for a maximum of 72 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0480-0389
Description: A single dose of subcutaneous NNC0480-0389. The study will last for a maximum of 72 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (NNC0480-0389)
Description: A single dose of subcutaneous placebo (NNC0480-0389) The study will last for a maximum of 72 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (NNC0480-0389)
Description: A single dose of subcutaneous placebo (NNC0480-0389) The study will last for a maximum of 72 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (NNC0480-0389)
Description: A single dose of subcutaneous placebo (NNC0480-0389) The study will last for a maximum of 72 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: A single dose of subcutaneous Semaglutide 0.5 mg The study will last for a maximum of 72 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: A single dose of subcutaneous Semaglutide 0.5 mg The study will last for a maximum of 72 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: A single dose of subcutaneous Semaglutide 0.5 mg The study will last for a maximum of 72 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Semaglutide)
Description: A single dose of subcutaneous placebo (semaglutide) The study will last for a maximum of 72 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Semaglutide)
Description: A single dose of subcutaneous placebo (semaglutide) The study will last for a maximum of 72 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Semaglutide)
Description: A single dose of subcutaneous placebo (semaglutide) The study will last for a maximum of 72 days.
Study: NCT05221606

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse AMIE
Description: Supportive Care Platform (behavioral interventions that are offered based on answers to daily symptom rating questions). Interventions offered include walking, balance, strength exercise, guided relaxation, mindfulness, CBT, DBT, soothing music.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Binder of written supportive care materials
Study: NCT06530537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: Cilostazol 100mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 100mg once daily
Study: NCT05300932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Orally take Baricitinib 4mg everyday for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Subject received cyclophosphamide 400mg intravenous drip every 2 weeks combined with oral Prednisone 10-15 mg/d （standard of care）through the 24 weeks double blind period. Subsequently, subject were administered oral Baricitinib 4mg everyday through the 24-48 weeks open label period.
Study: NCT06116188

Intervention type: DIAGNOSTIC_TEST
Intervention: FDG-PET study
Description: Hyperinsulinemic, euglycemic clamp technique will be used to promote tissue glucose uptake and measure insulin sensitivity. Two cannulas will be inserted, one in a radial or an antecubital vein for PET tracer injection and infusion of glucose and insulin, another in the opposite radial or antecubital vein for blood sampling. In the clamp study subjects are administered intravenous insulin at a steady rate of 40 mU/m2/min and normoglycemia is maintained using a variable rate infusion of 20% glucose based on plasma glucose measurements, which are performed every 5min from arterialized venous blood. We will also collect samples to determine plasma insulin, serum free fatty acid and metabolic biomarkers during the study.~The clamp will be performed together with \[18F\]-FDG-PET/CT.

Intervention type: DIAGNOSTIC_TEST
Intervention: FDG-PET study
Description: Hyperinsulinemic, euglycemic clamp technique will be used to promote tissue glucose uptake and measure insulin sensitivity. Two cannulas will be inserted, one in a radial or an antecubital vein for PET tracer injection and infusion of glucose and insulin, another in the opposite radial or antecubital vein for blood sampling. In the clamp study subjects are administered intravenous insulin at a steady rate of 40 mU/m2/min and normoglycemia is maintained using a variable rate infusion of 20% glucose based on plasma glucose measurements, which are performed every 5min from arterialized venous blood. We will also collect samples to determine plasma insulin, serum free fatty acid and metabolic biomarkers during the study.~The clamp will be performed together with \[18F\]-FDG-PET/CT.
Study: NCT05146466

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: E-MATVR
Description: It involves using computer software uploaded onto wireless virtual reality (VR) technology (similar to downloading an app on a mobile phone) and will be delivered using a headset, handheld controllers, and voiceover (all wireless). E-MATVR comprises three serious gaming levels aimed at familiarising men with the normal look and feel of the testes, common testicular symptoms and diseases, and the importance of early help-seeking.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: E-MATE
Description: It involves using the same information as EMATVR delivered as plain text (e.g., PDF) with still images from E-MATVR. Participants will be given approximately 10 minutes to read the text/look at images using a tablet (e.g., iPad).